Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury

• Published in: Asian Pacific journal of tropical medicine Vol. 8; no. 1; pp. 48 - 52
• Main Authors: Cheng, Hai-Feng, Feng, Yan, Jiang, Da-Ming, Tao, Kai-Yu, Kong, Min-Jian
• Format: Journal Article
• Language: English
• Published: India Elsevier B.V 2015
• Subjects: cardiac; Human; Human cardiac myocytes; injury; Ischemia-reperfusion; Ischemia–reperfusion injury; myocytes; Protection; Tocilizumab; Ischemia–reperfusion injury; Tocilizumab; Protection; Human cardiac myocytes
• ISSN: 1995-7645; 2352-4146
• DOI: 10.1016/s1995-7645(14)60186-3

Objective:To investigate the protective function of tocilizumab in human cardiac myocytes ischemia-reperfusion injury.Methods:The human cardiac myocytes were treated by tocilizumab with different concentrations(1.0 mg/mL,3.0 mg/mL,5.0 mg/mL) for 24 h.then cells were cultured in ischemia environment for 24 h and reperfusion environment for 1 h.The MTT and flow cytometry were used to detect the proliferation and apoptosis of human cardiac myocytes,respectively.The mRNA and protein expressions of Bcl-2 and Bax were measured by qRT-PCR and western blot,respectively.Results:Compared to the negative group,pretreated by tocilizumab could significantly enhance the proliferation viability and suppress apoptosis of human cardiac myocytes after suffering ischemia reperfusion injury(P<0.05).The expression of Bcl-2 in tocilizumab treated group were higher than NC group(P<0.05).while the Bax expression were lower(P<0.05).Conclusions:Tocilizumab could significantly inhibit apoptosis and keep the proliferation viability of human cardiac myocytes after suffering ischemia reperfusion injury.Tocilizumab may obtain a widely application in the protection of ischemia reperfusion injury.